Skip to main content

Shares in Sequenom Up 9.5 Percent on News of Qiagen Dx Alliance

NEW YORK (GenomeWeb News) — Shares in Sequenom were up 9.51 percent, or $.45, at $5.18, in mid-afternoon trading today after the company said it will work with Qiagen to develop a preanalytical product to enrich nucleic acids for prenatal diagnostics.
 
As GenomeWeb News reported this morning, Sequenom will retain commercial rights to any tests the companies develop under the partnership.
 
Qiagen said the goal for the partnership is to develop reliable reagents for the enrichment of small nucleic acid fragments, such as those found in maternal plasma, to analyze cancer and other disorders.
The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.